ORIGINAL RESEARCH

Effectiveness and safety of treatment with domestic cepeginterferon alpha-2b in patients with chronic hepatitis C infection. Actual clinical experience

Tkacheva SV1, Manapova ER1, Sozinova YuM1,2, Yakupova FM1,2, Fazylova YuV3
About authors

1 Department of Infectious Diseases, Faculty of Medical and Preventive Care,
Kazan State Medical University, Kazan, Russia

2 Diagnostic and Consultation Unit,
Agafonov Republican Clinical Hospital of Infectious Diseases, Kazan, Russia

3 Department of Dental Therapy, Faculty of Dentistry,
Kazan State Medical University, Kazan, Russia

Correspondence should be addressed: Svetlana Tkacheva
ul. Butlerova, d. 49, Kazan, Russia, 420012; ur.liam@umgk-avehcakt

About paper

All authors' contribution to this work is equal: selection and analysis of literature, planning of the manuscript's structure, data interpretation, drafting of the manuscript, editing.

Received: 2017-02-09 Accepted: 2017-03-10 Published online: 2017-06-02
|

Interferon-based regimens for chronic hepatitis C (HCV) are quite common, just like interferon-free treatments, and are extensively used in Russia because interferon is widely available to most patients. In 2013 the original Russian drug cepeginterferon alpha-2b (cepegIFN alpha-2b marketed as Algeron by Biocad, Russia) was introduced into clinical practice. The aim of this study was to assess effectiveness and safety of cepegIFN alpha-2b as part of the combination therapy with ribavirin in patients with chronic HCV infection. The study was conducted over the period from 2014 to 2016 and recruited 37 patients with chronic genotype 1 HCV infection: 22 men and 15 women (mean age of 42.0 ± 5.2 years). All of them received the following combination antiviral therapy (AT): 1.5 μg/kg cepegIFN alpha-2b once a week and 15 μg/kg ribavirin daily over the period of 48 weeks. Effectiveness of AT was assessed by the rate of sustained virological response (SVR), i. e. aviremia achieved 24 weeks after the onset of treatment. In our SVR was observed in 26 patients (70.3 %). Adverse effects seen in the course of AT were typical of interferon-based drugs and ribavirin. CepegIFN alpha-2b dosage was corrected in two patients who developed neutropenia; ribavirin dosage was corrected in 3 patients who developed anemia. Based on the obtained results, we recommend including cepegIFN alpha-2b into the combination antiviral therapy in patients with chronic HCV infection.

Keywords: chronic hepatitis C, HCV infection, antiviral therapy, cepeginterferon alpha-2b, ribavirin, virological response, treatment effectiveness

КОММЕНТАРИИ (0)